Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation ...

Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023. Pipeline ...

Researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery.

· The burden of both hypothyroidism and anaemia is on the rise. Anaemia amongst women between 15 and 49 years increased from ...

2-Year U.S. Treasury Note Continuous Contract $102.852-0.051-0.05% 5-Year U.S. Treasury Note Continuous Contract $106.688-0.172-0.16% 10-Year U.S. Treasury Note Continuous Contract $109.500-0.250 ...